Announcements Trials

Browse Landscape

Phase

Status

Recruiting 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 176 Neoplasms 173 Carcinoma, Non-Small-Cell Lung 152 Prostatic Neoplasms 108 Colorectal Neoplasms 105 Lung Neoplasms 91 Ovarian Neoplasms 82 Neoplasm Metastasis 76 Multiple Myeloma 72 Pancreatic Neoplasms 70 Leukemia, Myeloid, Acute 63 Endometrial Neoplasms 49 Squamous Cell Carcinoma of Head and Neck 47 Stomach Neoplasms 45 Melanoma 44 Lymphoma 44 Glioblastoma 42 Carcinoma, Renal Cell 42 Recurrence 41 Brain Neoplasms 41 Urinary Bladder Neoplasms 39 Carcinoma, Hepatocellular 39 Precursor Cell Lymphoblastic Leukemia-Lymphoma 38 Sarcoma 37 Glioma 36 Lymphoma, Non-Hodgkin 35 Hematologic Neoplasms 35 Leukemia, Lymphocytic, Chronic, B-Cell 34 Esophageal Neoplasms 33 Small Cell Lung Carcinoma 31

Interventions

relatlimab 1 pembrolizumab 1 lifileucel 1 Temozolomide 1 Paclitaxel 1 Opdualag 1 Nivolumab 1 Ipilimumab 1 Dacarbazine 1 Carboplatin 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Melanoma, Cutaneous Malignant × 30 days × Clear all

NCT06743126 2026-05-29

SUPRAME

Immatics US, Inc.

Phase 3 Recruiting

Melanoma, Cutaneous Malignant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡